Fisher Asset Management LLC lowered its stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 17.5% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 152,498 shares of the technology company’s stock after selling 32,377 shares during the period. Fisher Asset Management LLC’s holdings in Cogent Biosciences were worth $4,883,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in COGT. Knights of Columbus Asset Advisors LLC raised its stake in shares of Cogent Biosciences by 11.0% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 55,666 shares of the technology company’s stock worth $1,782,000 after purchasing an additional 5,510 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Cogent Biosciences by 2.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 15,078 shares of the technology company’s stock valued at $476,000 after purchasing an additional 405 shares in the last quarter. Pictet Asset Management Holding SA lifted its holdings in shares of Cogent Biosciences by 18.8% in the third quarter. Pictet Asset Management Holding SA now owns 2,842,776 shares of the technology company’s stock valued at $90,990,000 after purchasing an additional 449,261 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Cogent Biosciences in the third quarter valued at approximately $284,000. Finally, Profund Advisors LLC boosted its position in shares of Cogent Biosciences by 30.7% during the third quarter. Profund Advisors LLC now owns 60,425 shares of the technology company’s stock valued at $1,935,000 after buying an additional 14,199 shares during the last quarter.
Wall Street Analyst Weigh In
COGT has been the subject of several recent research reports. Piper Sandler upped their price target on Cogent Biosciences from $52.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. HC Wainwright raised their price objective on Cogent Biosciences from $55.00 to $56.00 and gave the company a “buy” rating in a research note on Monday, November 9th. Wall Street Zen downgraded shares of Cogent Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, September 5th. Guggenheim upped their target price on shares of Cogent Biosciences from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cogent Biosciences in a report on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $53.57.
Check Out Our Latest Stock Report on COGT
Cogent Biosciences Stock Performance
COGT stock opened at $27.44 on Tuesday. The firm has a market cap of $4.77 billion, a PE ratio of -12.20 and a beta of 0.36. The company has a quick ratio of 13.57, a current ratio of 10.99 and a debt-to-equity ratio of 0.50. The business has a 50 day moving average of $31.25 and a 200-day moving average of $35.26. Cogent Biosciences, Inc. has a 12-month low of $27.23 and a 12-month high of $43.73.
Cogent Biosciences (NASDAQ:COGT – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The technology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). As a group, sell-side analysts expect that Cogent Biosciences, Inc. will post -2.28 earnings per share for the current year.
Cogent Biosciences Profile
Cogent Biosciences is a clinical-stage biotechnology company developing precision medicines for diseases driven by specific genetic mutations. Its research focuses on targeted therapies intended to address the underlying causes of these conditions. The company’s lead investigational medicine, bezuclastinib, is a selective inhibitor of the KIT protein. Cogent has studied it in clinical programs for systemic mastocytosis and gastrointestinal stromal tumors (GIST), conditions in which abnormal KIT signaling can play a role.
Recommended Stories
- Five stocks we like better than Cogent Biosciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding COGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report).
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
